October Pharma results, Fiscal year 2022
Net profit, assets, equity and cash flow for Fiscal year 2022, against the same period a year earlier, from the published financial statements.
Net profit131 millionEGP · +9.1% vs the same period a year earlier
Total assets950 millionEGP · +71.8% vs the same period a year earlier
Shareholders' equity426 millionEGP · +25.4% vs the same period a year earlier
Operating cash flow-92.33 millionEGP · −135.2% vs the same period a year earlier
In short
- October Pharma's net profit for Fiscal year 2022 was about 131 million EGP, up +9.1% from 120 million EGP in Fiscal year 2021.
- Total assets at the end of Fiscal year 2022 were about 950 million EGP, and shareholders' equity about 426 million EGP.
- Operating cash flow for Fiscal year 2022 was negative at 92.33 million EGP.
Key lines against the same period a year earlier
This periodFiscal year 2021Change
Net profit131 million120 million+9.1%
Gross profit370 million335 million+10.4%
Total assets950 million553 million+71.8%
Total liabilities524 million214 million+145.5%
Shareholders' equity426 million339 million+25.4%
Total liabilities and equity950 million553 million+71.8%
Operating cash flow-92.33 million262 million−135.2%
Investing cash flow-94.31 million-21.4 million−340.7%
Financing cash flow177 million-226 million+178.3%
Net change in cash-9.81 million14.86 million−166.0%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
October Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy